| Literature DB >> 29385292 |
Ping Zhang1, Nopphon Weeranoppanant2, Dale A Thomas3, Kohei Tahara4, Torsten Stelzer5, Mary Grace Russell3, Marcus O'Mahony6, Allan S Myerson3, Hongkun Lin3, Liam P Kelly3, Klavs F Jensen3, Timothy F Jamison3, Chunhui Dai3, Yuqing Cui3, Naomi Briggs3, Rachel L Beingessner3, Andrea Adamo3.
Abstract
As a demonstration of an alternative to the challenges faced with batch pharmaceutical manufacturing including the large production footprint and lengthy time-scale, we previously reported a refrigerator-sized continuous flow system for the on-demand production of essential medicines. Building on this technology, herein we report a second-generation, reconfigurable and 25 % smaller (by volume) continuous flow pharmaceutical manufacturing platform featuring advances in reaction and purification equipment. Consisting of two compact [0.7 (L)×0.5 (D)×1.3 m (H)] stand-alone units for synthesis and purification/formulation processes, the capabilities of this automated system are demonstrated with the synthesis of nicardipine hydrochloride and the production of concentrated liquid doses of ciprofloxacin hydrochloride, neostigmine methylsulfate and rufinamide that meet US Pharmacopeia standards.Entities:
Keywords: active pharmaceutical ingredients; continuous flow chemistry; industrial chemistry; synthetic methods
Mesh：
Substances：
Year: 2018 PMID： 29385292 DOI： 10.1002/chem.201706004
Source DB: PubMed Journal: Chemistry ISSN： 0947-6539 Impact factor: 5.236